{"filing":{"accession_number":"0001193125-26-343428","cik":"0001534133","ticker":"CALC","company_name":"CalciMedica, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"ck0001534133-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/ck0001534133-20260811.htm"},"events":[{"id":26864,"run_id":24432,"accession_number":"0001193125-26-343428","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CalciMedica issued a press release on August 11, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 cash position ($18.6 million), R\u0026D expenses ($2.1 million), G\u0026A expenses ($1.9 million), and net loss ($7.7 million or $0.45 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28142,"accession_number":"0001193125-26-343428","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CalciMedica issued a press release on August 11, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 cash position ($18.6 million), R\u0026D expenses ($2.1 million), G\u0026A expenses ($1.9 million), and net loss ($7.7 million or $0.45 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:16:38.211732+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28142,"accession_number":"0001193125-26-343428","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CalciMedica issued a press release on August 11, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 cash position ($18.6 million), R\u0026D expenses ($2.1 million), G\u0026A expenses ($1.9 million), and net loss ($7.7 million or $0.45 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:16:38.211732+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-08-11"}]}